# HighCape Partners

HighCape Partners is an Asset Manager based in Westport, United States.

## Overview

- **Organization type:** Asset Manager
- **Headquarters:** Westport, United States
- **Region:** North America
- **Address:** Westport, CT, United States
- **Founded:** 2013
- **Assets under management:** Undisclosed
- **Website:** www.highcape.com
- **LinkedIn:** https://www.linkedin.com/company/highcape-capital

## Regulatory record

- **CRD number:** 170971
- **SEC file number:** 802-79517
- **Registration status:** Registered
- **Reports private funds:** Yes
- **IAPD record:** https://adviserinfo.sec.gov/firm/summary/170971

## About

HighCape Capital is a growth equity fund that assists Life Sciences companies in transitioning to established organizations. It was formed in 2013 by experienced executives. Team members have backgrounds in founding, financing, growing, and exiting Life Sciences companies.

## Sectors

- Life Sciences
- Medical Devices
- Biotechnology

## People

- Kevin Rakin — Co-Founder & Partner
- Matt Gline — Co-Founder & Partner

## Questions

### Does HighCape operate as a traditional venture firm or a SPAC sponsor?

HighCape functions primarily as a SPAC sponsor with growth equity capabilities. Its first vehicle, HighCape Capital Acquisition Corp., raised $115 million in a September 2020 IPO and completed a merger with Quantum-Si in June 2021. The firm's strategy involves identifying a single platform company per vehicle and providing operational leadership post-close, rather than managing a diversified early-stage portfolio.

### What investment stages does HighCape target?

HighCape targets commercial-stage life sciences companies — those with existing FDA clearance or approval that require operational and commercial expertise to scale. This sits between early-stage venture capital, which funds pre-approval research, and late-stage buyouts, which target mature, diversified platforms. The firm has publicly stated its focus on growth-stage opportunities where technology risk is reduced and commercial execution is the primary value driver.

### How is HighCape related to Quantum-Si?

HighCape Capital Acquisition Corp., the firm's SPAC vehicle, merged with Quantum-Si in June 2021 to take the company public on Nasdaq under the ticker QSI. Following the merger, HighCape partners Kevin Rakin and Matt Gline joined the Quantum-Si board. The transaction provided Quantum-Si with approximately $500 million in gross proceeds to commercialize its single-molecule protein sequencing platform.

### Does HighCape invest alongside external GPs or co-investors?

HighCape's SPAC structure inherently involves institutional co-investors through the PIPE (private investment in public equity) process. The firm has not publicly disclosed a fund-of-funds program or traditional LP co-investment vehicle. Its capital base includes family offices and institutional investors who participated directly in the HighCape Capital Acquisition Corp. IPO and subsequent Quantum-Si transaction.

### What is the professional background of HighCape's founders?

Kevin Rakin co-founded Advanced BioHealing, a regenerative medicine company acquired by Shire in 2011 for $750 million. He has served on boards of multiple life sciences companies including Quantum-Si. Matt Gline was CFO of Dermira, a dermatology biotech that went public in 2014, guided it through multiple financing rounds, and remained through its 2020 acquisition by Eli Lilly for $1.1 billion. Both bring operator rather than traditional private equity backgrounds.

## Related profiles

- [Highbury Group](https://altss.com/profile/highbury-group)
- [High Circle Ventures](https://altss.com/profile/high-circle-ventures)

---

Last updated: 2026-07-11T16:25:51.000Z

Canonical page: https://altss.com/profile/highcape-partners

Maintained by Altss — https://altss.com — methodology: https://altss.com/methodology